top of page

ADVERTISEMENT

Therasage Fall Banner.jpg
Mid slider ad reduced.jpg
MHI Square 2.jpg

ADVERTISEMENT

Our top picks

MAHA Inaugural Ball

EXCLUSIVE COVERAGE

Donald Trump

TRUTH AND TRANSPARENCY

Trump wins 2024 election

RFK JR

Pursuit of Pet Longevity

FUREVER FAITHFUL

ADVERTISEMENT

Pfizer Kickbacks Lawsuit Settlement: Company To Pay $60M Over Kickbacks For Nurtec ODT


Photo: Dr. Korom/ CC BY-SA 2.0
Photo: Dr. Korom/ CC BY-SA 2.0

Pfizer Inc. has agreed to pay $59,746,277 to settle allegations that it engaged in improper kickback practices to promote its migraine drug Nurtec ODT (Rimegepant), according to the U.S. Department of Justice (DOJ).


The settlement resolves claims that Biohaven Pharmaceutical Holding Company Ltd., a wholly-owned subsidiary of Pfizer, violated the False Claims Act by paying kickbacks—such as speaker honoraria and meals at high-end restaurants—to healthcare providers to induce prescriptions of Biohaven’s Nurtec ODT. These practices, which happened before Pfizer acquired the company, allegedly led to false claims submitted to federal healthcare programs like Medicare and Medicaid.


"Patients deserve to know that their doctor is prescribing medications based on their doctor’s medical judgment, and not as a result of financial incentives from pharmaceutical companies," said U.S. Attorney Trini E. Ross in a press release published by the Department of Justice.


"This settlement reflects our commitment to hold those who violate the laws accountable, regardless of their status or prestige."


Nurtec ODT, a treatment for migraines, was widely marketed, including a high-profile campaign with pop star Lady Gaga in 2019.


Nurtec ODT, also known as Rimegepant, is an FDA-approved orally disintegrating tablet used for the acute treatment and prevention of migraines. It works by blocking CGRP, a protein involved in migraine attacks.


The drug was promoted by singer Lady Gaga in 2023 and again, in 2024. The singer shared that she had suffered from migraines since childhood and wished she had found the drug sooner. 


Without admitting liability, Pfizer agreed to the settlement to avoid further litigation. The nearly $60 million will reimburse federal healthcare programs and address civil fraud allegations.


The settlement resolves claims under the False Claims Act’s qui tam provisions, brought by whistleblower Patricia Frattasio, a former Biohaven sales representative. These provisions allow private individuals to sue on behalf of the U.S. and receive a portion of the recovery. Of the nearly $60 million settlement, Frattasio will receive $8.4 million as her share of the federal recovery.


Disclaimer:

The information provided here is for entertainment and educational purposes only. It is not intended to substitute medical professional advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Visit the disclaimer link for more details: www.biohackyourself.com/termsanddisclaimers

0 comments

Commenti


Therasage Fall Banner.jpg
Mid slider ad reduced.jpg
MHI Square 2.jpg
bottom of page